Elpiscience Biopharmaceuticals Co.
Latest round
- Series C
Last raised
- May 2021
Total raised
- $260M
Investors
- 17
About Elpiscience Biopharmaceuticals Co.
Based in Shanghai, China, and established in 2017 by CEO Darren Ji and Hongtao Lu, Elpiscience Biopharmaceuticals Co. Ltd. also called Elpiscience (Shanghai) Biopharma, Ltd. is a clinical-stage biopharmaceutical company that focuses on cancer immunotherapy. The company employs clinical manufacturing capabilities ranging from process development, analytics, quality control/assurance, and pilot, and cGMP manufacturing. The company has collaborated with Bio-Techne for the co-development of novel immunotherapies. As of 2021, the company employs over 100 employees. The company also established branches in Suzhou, and USA. The company’s pipeline consists of more than 15 molecules in discovery focusing on innate immunity and tumor microenvironment and comprises of four major categories: adaptive immunity, innate immunity, tumor microenvironment, and tumor-specific antigens. The company focuses on biological insights to find differentiated biology in a complex immune system to eradicate tumors. Elpiscience’s pipeline drugs consist of three assets: ES101, ES102, and ES104, in the Phase I development stage of clinical trials. Elpiscience also provides a discovery platform that consists of three major parts: Elpisource™, a novel target discovery platform comprising of a knockout (KO) system and an overexpression system to identify specific genes required for an immune response; Immonushine™, an integrated immunology assay platform used to screen candidate drugs and assess their properties in primary immune cells and established immune cell lines; and AbLego™, a proprietary bispecific antibody platform consisting of multiple antibody formats and a systematic approach for bispecific molecules optimization. The company plans on advancing ES101 band ES104 to the Phase II of the development stage by 2021 and 2022 respectively., Ltd.
Who invested in Elpiscience Biopharmaceuticals Co.
17 investors across 5 rounds
See all investors in Elpiscience Biopharmaceuticals Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Elpiscience Biopharmaceuticals Co.
Who invested in Elpiscience Biopharmaceuticals Co.?
Elpiscience Biopharmaceuticals Co. has 17 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Elpiscience Biopharmaceuticals Co. raised?
Elpiscience Biopharmaceuticals Co. has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Elpiscience Biopharmaceuticals Co. last raise money?
Elpiscience Biopharmaceuticals Co.'s most recent round on record is a Series C, in May 2021.
What does Elpiscience Biopharmaceuticals Co. do?
Based in Shanghai, China, and established in 2017 by CEO Darren Ji and Hongtao Lu, Elpiscience Biopharmaceuticals Co.
Where is Elpiscience Biopharmaceuticals Co. headquartered?
Elpiscience Biopharmaceuticals Co. is headquartered in Shanghai, China.
Which VCs invest in companies like Elpiscience Biopharmaceuticals Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Elpiscience Biopharmaceuticals Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Elpiscience Biopharmaceuticals Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.